Sivignon, M., Monnier, R., Tehard, B., & Roze, S. (2020). Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France. PLoS One.
Παραπομπή Chicago StyleSivignon, Marine, Rémi Monnier, Bertrand Tehard, και Stéphane Roze. "Cost-effectiveness of Alectinib Compared to Crizotinib for the Treatment of First-line ALK+ Advanced Non-small-cell Lung Cancer in France." PLoS One 2020.
Παραπομπή MLASivignon, Marine, Rémi Monnier, Bertrand Tehard, και Stéphane Roze. "Cost-effectiveness of Alectinib Compared to Crizotinib for the Treatment of First-line ALK+ Advanced Non-small-cell Lung Cancer in France." PLoS One 2020.
Πρόσοχή: Οι παραπομπές μπορεί να μην είναι 100% ακριβείς.